<DOC>
	<DOCNO>NCT02547428</DOCNO>
	<brief_summary>This Phase IIb , randomize , double-blind , multicenter , 2-period , 2-treatment , crossover study evaluate safety , efficacy , duration efficacy CTN SR BID target total daily dose ( TDD ) 400 mg compare placebo adult ADHD .</brief_summary>
	<brief_title>Safety Efficacy Study Centanafadine Sustained-Release ( CTN SR ) Adults With Attention-Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Participant 18 60 year age , inclusive , time consent 2 . Participant meet Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) criteria primary diagnosis ADHD , presentation , establish comprehensive psychiatric evaluation base DSM5 criterion least 5 9 subtype criterion meet , determine Conners ' Adult ADHD Diagnostic Interview Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) ( CAADID Part II ) 3 . Participant Baseline score great equal 28 use ADHDRSIV 4 . Participant minimum score 4 CGIS Baseline 5 . Participant function ageappropriate level intellectually , judge Investigator 1 . Participant current comorbid psychiatric disorder either control medication prohibit study uncontrolled associate significant symptom . Exclusionary condition include severe comorbid Axis II disorder severe Axis I disorder ( posttraumatic stress disorder [ PTSD ] , psychosis , bipolar illness , severe obsessive compulsive disorder , severe depressive severe anxiety disorder ) symptomatic manifestation , opinion examine physician , contraindicate CTN SR treatment confound efficacy safety assessment . Specifically , participant mild moderate form Axis I disorder ( e.g. , social phobia dysthymia ) may include , whereas participant lifetime history psychosis bipolar disorder exclude . Comorbid psychiatric diagnosis establish SemiStructured Clinical Interview DSM5 Axis I Disorders ( Mini lnternational Neuropsychiatric lnterview , Version 6.0 [ M.I.N.I . 6.0 ] ) . 2 . Participants currently consider suicide risk , participant previously make suicide attempt , currently demonstrate active suicidal ideation measure ColumbiaSuicide Severity Rating Scale ( CSSRS ) Screening , opinion investigator participant consider suicide risk . Participants develop suicidal ideation behavior trial measure CSSRS discontinue follow appropriately . 3 . The participant body mass index ( BMI ) less 18.5 great equal 40 Baseline 4 . Participant concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition might confound result safety assessment administer study might increase risk participant 5 . Participant history seizure ( infantile febrile seizure ) , tic disorder ( except transient tic disorder participant episodes great equal 1 year ) , current diagnosis and/or know family history Tourette 's Disorder ( i.e . first degree relative ) 6 . Participant known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , transient ischemic attack stroke serious cardiac problem may place increased vulnerability potential sympathomimetic effect 7 . Participant know family history sudden cardiac death ventricular arrhythmia 8 . Participant history significant bleeding coagulation disorder and/or low platelet level ( less 130 X 109/L ) increase international normalized ratio ( INR ) ( great 1.3 ) Screening 9 . Participant history cancer 10 . Participant clinically significant 12lead ECG clinically significant laboratory abnormality Screening and/or Baseline 11 . Participant current abnormal thyroid function , define abnormal Screening thyroid stimulate hormone ( le 0.34 great 5.6 Î¼IU/mL ) . Treatment stable dose thyroid medication least 3 month permit . 12 . Participant rest sit systolic blood pressure ( SBP ) great equal 140 mm Hg diastolic blood pressure ( DBP ) great equal 90 mm Hg . No 1 repeat measurement permit . 13 . Participant history hyponatremia 14 . Participant antihypertensive medication kind 15 . Participant known history orthostatic hypotension orthostatic blood pressure drop great equal 20 mm Hg ( base drop sit stand [ 3 minute ] SBP ) Screening Baseline 16 . Participant known history hypertension 17 . Participant exhibit lifestyle may confound safety efficacy assessment per judgment investigator ( e.g . exercise , diet travel extensively ) 18 . Participant known history glaucoma 19 . Participant fail respond 1 adequate course ( e.g. , adequate dose duration poor response judge Investigator ) stimulant therapy 20 . Participant recent history ( within past 6 month ) suspect substance abuse dependence disorder ( exclude nicotine ) accordance DSM5 criterion 21 . Participant take medication central nervous system ( CNS ) effect affect performance , sedate antihistamine decongestant sympathomimetic , recently monoamine oxidase inhibitor ( within 14 day investigational product [ IP ] administration ) . Stable use bronchodilator inhaler exclusionary . This also include use psychoactive prescription medication within 30 day prior Screening psychoactive overthecounter ( OTC ) medication herbal product require 7day washout . Participants currently treat methylphenidate amphetamine product permit undergo 7day washout period . Participants take atomoxetine require undergo 30day washout . 22 . Participant require frequent regular use aspirin , ibuprofen , naproxen sodium , anticoagulant , warfarin 23 . Participants take known potent inhibitor inducer common cytochrome P450 ( CYP ) enzyme , include herbal product 24 . Participant positive urine drug screen ( UDS ) result Screening Baseline . NOTE : The UDS must negative Screening ( exception participant 's current ADHD psychostimulant , applicable ) Baseline , applicable , participant potentially eligible study participation . The Investigator , conjunction Medical Monitor , evaluate potential impact positive UDS regard continued participation participant . 25 . Participant take investigational product take part clinical study within 30 day prior Screening 26 . Investigational site personnel permit participate study 27 . Participant participate previously CTN investigational study 28 . The female participant pregnant lactate 29 . Participant document allergy , hypersensitivity , intolerance CTN excipients reference product 30 . Participant history allergy hypersensitivity medication ( e.g. , monoamine reuptake inhibitor antibiotic ) 31 . Participant agree unable abstain consume alcohol study Reproductive Potential Requirements 32 . All female participant require negative serum beta human chorionic gonadotropin ( HCG ) pregnancy test Screening , negative urine pregnancy test Baseline , either postmenopausal ( 12 consecutive month spontaneous amenorrhea great equal 51 year age ) , surgically sterile least 6 week poststerilization , females childbearing potential , negative pregnancy test prior enter study agree use acceptable method contraception Contraceptive Requirements 33 . Condoms use form contraception ( i.e. , doublebarrier method ) . Acceptable contraceptive include follow : 1 . Intrauterine device 2 . Hormonal contraceptive ( oral , depot , patch , injectable , vaginal ring ) 3 . Diaphragms spermicidal gel foam 34 . Females childbearing potential advise use acceptable contraceptive date inform consent throughout study period define followup period 35 . If hormonal contraceptive use , administer accord package insert 36 . Females childbearing potential currently sexually active agree use acceptable contraception , define , become sexually active study participation define followup time period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>